March 21st 2019
Imugene gains guidance for KEY-Vaxx Immunotherapy development
March 14th 2019
First patient dosed in phase 2 trial with Imugene’s gastric cancer vaccine
March 4th 2019
Imugene to present cancer vaccine programs to the American Association for Cancer Research
February 28th 2019
Cashed up Imugene to present at American Association for Cancer Research
January 7th 2019
Imugene onboards renowned cancer scientist Michael Caligiuri
December 17th 2018
Imugene's promising trial results: five patients with >30% decrease in tumour size
November 13th 2018
Imugene's gastric cancer immuno-oncology trial advances to Phase 2
November 9th 2018
Good run continues for Imugene with $1.85M R&D tax incentive
October 3rd 2017
Immuno-oncology: a new horizon in the fight against cancer
September 26th 2017
Is IMU on the path to a viable cure for cancer?
June 16th 2017
Merger and acquisition activity heightens in healthcare sector
May 17th 2017
Will Imugene’s expertise in immunotherapies result in an AstraZeneca type rerating?
April 7th 2017
Support from leading institutional investors augurs well for Imugene
March 30th 2017
How Imugene is tackling gastric cancer
Connect with us
Subscribe to our weekly wrap.
Thanks for subscribing!